Émilie Routier
Université Paris-Saclay(FR)Institut Gustave Roussy(FR)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, CAR-T cell therapy research, Immunotherapy and Immune Responses, Cutaneous Melanoma Detection and Management
Most-Cited Works
- → Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab(2017)1,280 cited
- → Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination(2016)1,087 cited
- → Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab(2015)641 cited
- → eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies(2014)354 cited
- → Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study(2019)307 cited
- → Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease(2018)307 cited
- → Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival(2013)307 cited
- → Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma(2018)258 cited
- → Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients(2013)203 cited
- → Kidney injuries related to ipilimumab(2014)168 cited